Sciences Center (Shreveport, LA). Information related to clinical history, neuroimaging, microsurgical dissection, and outcomes of the patients who underwent implantation of an SCS between January 2001 and June 2015 was collected retrospectively by review of each patient's case notes, follow-up chart, and radiology reports.
Patient selection

Demographic Data of Patients and Chronic Back Pain Characteristics
A total of 141 patients with chronic back pain underwent implantation of a paddle lead SCS between 2001 and 2015. All cases underwent an initial trial using a percutaneous SCS before starting its use as a definitive treatment for chronic pain. In this series, the average age of patients was 59 years (range 26-80 years). Of these 141 patients, 68 (48.2%) were men and 73 (51.8%) were women. One hundred twenty-one (85.6%) of the patients were white and 20 (14.2%) were African American. In this series, common indications for implantation of the SCS were FBSS and chronic back pain (e.g., lumbar neuropathy, sciatica) with failure of conservative management. The mean preimplantation pain score was 8 (range 7-9) ( Table 1) .
Procedure for SCS Implantation
We recruited patients for permanent placement of leads after completion of a successful trial with a percutaneous SCS to avoid spinal surgery. The results of the trial determined the number of leads, electrodes, and proper placement of leads for pain coverage. The patient was placed prone with proper protection of pressure points. With the help of a fluoroscope, the pedicle of the targeted spinal segment was marked. The skin over the entry zone was prepared with antiseptic solution and draped. The senior author (B.G.) preferred the left paramedian incision. A mini-laminectomy was performed using a standard approach. Flavectomy and minimal resection of superior and inferior lamina was performed to create a space for the paddle lead. A paddle lead was then placed in the median position, with tunneling of 2 extension cables through the left paramedian space. Later, the cables were connected with implanted pulse generators in the left subcutaneous area. The final position of the lead was confirmed with fluoroscopy ( Figs. 1 and 2 ).
Patient Follow-Up
Preoperative and follow-up data were collected from the study population. Radiographs of the thoracolumbar region were obtained at 3-month intervals during the 1st year after placement of the SCS and at 6-month intervals for subsequent years. The median duration of follow-up was 31.49 months (3-166 months).
statistical Analysis
Commercially available software, SPSS version 21.0 (SPSS, Inc.), was used for statistical analysis. The KaplanMeier method of survival analysis was used to estimate revision-free survival (RFS). The log-rank (Mantel-Cox) test was used to analyze the survival difference in the cases. A Cox proportional hazards regression model was used to determine independent significant factors for RFS. When necessary, the chi-square test was used. A p value < 0.05 was considered significant.
results
The mean preimplantation pain score was 8 (range 7-9). There was no significant difference in mean preimplantation pain score between groups. However, the mean pain score at last follow-up was 1.38 (range 0-7). There was a significant difference between mean pre-and postimplantation pain scores between groups (Table 2) .
Ninety cases (64%) did not require any further intervention; for 14 patients, removal of the SCS was required. Among these 14 patients, 9 did not need the SCS anymore because they no longer experienced substantial pain. However, 5 patients required a different surgical intervention (laminectomy) to control the pain. Forty-six patients (32.6%) underwent SCS revision for several reasons (Table 3).
Causes of sCs revision
The leading causes of revision were hardware-related problems (nonfunction/malfunction), followed by infection and migration of the lead. The median time to revision was 25.37 months (range 3-145 months; Table 3 ).
revision-Free survival outcome
The overall median RFS was 43 months. The RFS rate after 1, 3, and 5 years was 75%, 65%, and 45%, respectively (Fig. 3) .
Effect of Age on RFS
The median RFS for patients ≥ 60 years was 56 months, and in patients < 60 years it was 38 months. This difference in the median RFS between the 2 groups reached statistical significance (log-rank p = 0.02) (Fig. 4A ).
Effect of Male or Female Sex on RFS
The median RFS for men was 25 months, and in women it was 43 months. This difference in the median RFS between the 2 groups reached statistical significance (logrank p = 0.03) (Fig. 4B ).
Effect of Race on RFS
The median RFS for white patients was 38 months, and for African American patients it was 34 months. This dif- ference in the median RFS between the 2 groups did not reach statistical significance (log-rank p = 0.30) (Fig. 4C ).
Effect of Obesity on RFS
The median RFS for patients with a body mass index (BMI) ≥ 30 kg/m 2 was 25 months, and for patients with a BMI < 30 kg/m 2 it was 41 months. This difference in the median RFS between the 2 groups achieved statistical significance (log-rank p = 0.03) (Fig. 5 left) .
Effect of Diabetes Mellitus on RFS
The median RFS in patients with diabetes mellitus (DM) was 35 months, and in patients without DM it was 43 months. This difference in the median RFS between the 2 groups did not reach statistical significance (log-rank p = 0.98) (Fig. 5 right) .
Effect of Preimplantation Pain Score on RFS
The median RFS in patients with a pain score < 8 was 59 months, and in patients with a pain score ≥ 8 it was 33 months. This difference in the median RFS between the 2 groups reached statistical significance (log-rank p = 0.02) (Fig. 6A) .
Effect of Neuromuscular Pain on RFS
The median RFS in patients with neuromuscular pain (mostly fibromyalgia) was 18 months, and in patients without neuromuscular pain it was 59 months. This difference in the median RFS between the 2 groups reached statistical significance (log-rank p < 0.0001) (Fig. 6B) .
Effect of Depression on RFS
The median RFS in patients with depression was 34 months, and in patients without depression it was 56 months. This difference in the median RFS between the 2 groups did not reach statistical significance (log-rank p = 0.22) (Fig. 6C) .
outcomes During early Follow-Up (< 6 Months) After implantation of sCs
The median RFS during early follow-up was 5.6 months (range 3.4-5.8 months). In this series, 5 cases (2.4%) required revision within 6 months of initial SCS implantation (Table 3) .
Factors for revisions required within First 6 Months of sCs implantation
Preimplantation Pain Score
The median RFS in patients with a pain score < 8 was 6 months, and in patients with a pain score ≥ 8 it was 4 months. This difference in the median RFS between the 2 groups reached statistical significance (log-rank p = 0.005) (Fig. 7A) .
Obesity/Higher BMI
The median RFS in patients with a BMI ≥ 30 kg/m 2 was 5 months, and in patients with a BMI < 30 kg/m 2 it was 6 months. This difference in the median RFS between the 2 groups did not reach statistical significance (log-rank p = 0.12) (Fig. 7B) .
Neuromuscular Pain
The median RFS in patients with neuromuscular pain (mostly fibromyalgia) was 5 months, and in patients without neuromuscular pain it was 6 months. This difference in the median RFS between the 2 groups did not reach statistical significance (log-rank p = 0.09) (Fig. 7C) .
Factors Predictive of required revision After sCs implantation
Cox regression was performed to identify the predictors of revision in patients who underwent SCS implantation; the results are shown in Tables 4 and 5 . The following covariates were included in the model: age (≥ 60 years vs < 60 years), sex (male vs female), race (white vs African American), obesity (yes vs no), DM (yes vs no), preimplantation pain score (≥ 8 vs < 8), neuromuscular pain (yes vs no), and depression (yes vs no). Among the listed factors, age < 60 years, male sex, obesity, neuromuscular pain, and a preimplantation pain score ≥ 8 were identified as predictors of earlier requirement for revisions. In multivariate analysis, age < 60 years, male sex, and neuromuscular pain were revealed as predictors of shorter RFS. However, race, depression, and DM did not show any significant relationships with revisions in this study.
In an earlier outcome study, we determined the predictors (obesity, preimplantation pain, and neuromuscular pain) of SCS revision. However, in univariate and multivariate analyses, only a preimplantation pain score ≥ 8 was identified as a predictor of early failure of SCS implantation.
Discussion
The clinical use of SCSs for chronic severe pain has been increasing due to better safety, efficacy, and costeffectiveness. 6, 16 Significant advancements of hardware, programming algorithms, anchoring options, and surgical techniques have minimized complications and requirements for revisions of SCSs. 13, 16, 19 However, despite this improvement, the requirement for SCS revision is not uncommon. 13 In this series, we investigated the outcomes of SCS implantation as treatment for intractable back pain and we established the predictors of requirements for early and late revisions.
Pain relief
One objective of this study was to evaluate pain relief after SCS implantation. In our series, there was significant relief of pain after SCS implantation, which is consistent with the previous study by Matias et al. 13 The average decrease in pain score was more than 6 points. The degree of pain relief was associated with the indication for revision of SCS or spine surgery such as laminectomy.
Complications and requirements for early and late sCs revision
Although SCS implantation is an efficacious treatment for intractable pain, it is not without complications. In our series, the complications rate was 36%, which is consistent with the findings of earlier studies with ranges from 31.6% to 54.6%. 6, 14, 22 The most common indications for revision were nonfunction or malfunction of the hardware, migration of the lead, and infection. In this series, more than 50% of revision cases required revisions due to nonfunc- tion of the SCS hardware, and this result is in agreement with the findings of previous reports. 6, 14, 22 Surprisingly, the percentage (2.1%) of lead migration was comparatively lower than that in an earlier report. 6 This finding can be explained by the following factors. 1) The use of paddle leads in all cases of our series. 13 2) Improvement in the delivery of stimulators over time, because the revision rate decreased with more experience of the surgeons and higher familiarity with SCSs. In this series, the revision rate was 53% in earlier cases (before 2011) and 29% in later cases (during or after 2011) (p = 0.007). 3) Advancement in surgical technique, including better anchoring of the SCS, which in turn may represent a trend toward a decreased incidence of lead migration. 6 Infection was the biological complication in our series, with a rate of 2.8%. This finding is comparable to results in the literature, with reported ranges of 3.4%-8.6%. 6, 9, 14, 21, 22 In our series, no patient experienced meningitis, and infections were managed by removal of the SCS and intravenous antibiotics. 
revision timeline
As would be expected, earlier revisions were performed among patients who developed infections after implantation. The median time to revision among these patients was 5.6 months, which is shorter compared with the time to revision for hardware-related complications. 6 In our series, the median time to revision for hardware-related complications (e.g., nonfunction) was 23 months, but loss of functional activity of the SCS could occur at any time (range 5-122 months). The causal factor of hardware-related complications is not well established in the literature, and further investigation is needed on the long-term efficacy of SCS implantation. 6 In this series, 40% of revisions were among patients with FBSS, and this is consistent with the previous report by Sears et al. 20 There were 30 patients (21%) with axial back pain and 111 patients (79%) with neuropathic pain. Among patients with axial back pain, 50% of cases required revision. However, among patients with neuropathic pain, only 34% of cases required revision. 2, 5, 6, 10, 15, 17 In addition, in this study, the median RFS was 28 and 47 months for axial back pain and neuropathic pain, respectively (p = 0.39; Fig. 8 ).
Previous studies showed that based on SCS type, requirements for revision and complications varied. 6, 20 Because we performed paddle lead SCS implantation after confirming the efficacy with percutaneous SCS implantation, it is difficult to compare the efficacy and complications of these 2 types of hardware. However, an earlier report 1 showed that the overall (> 5 years) reoperation rate was approximately 3 times higher in percutaneous lead SCS implantation (22.9% vs 8.5%). The complication rate was slightly higher in paddle lead SCS implantation (3.4% vs 2.2%).
In addition, patients who received percutaneous lead SCS implantation (which cost $30,200) had higher hospitalization costs than those who underwent paddle lead SCS implantation (which cost $29,963). One-and 2-year outpatient use and costs were significantly higher in the percutaneous lead SCS implantation group ($50,793) compared with the paddle lead SCS implantation group ($37,147).
Predictors of sCs revision
On the basis of the literature, predictors of requirement for SCS revision are not well established. Recently, De La Cruz et al. showed that drug use and active smoking were positive predictors of early SCS revision. 4 In the present study, we attempted to identify the predictors of both early and overall revision of SCS. Our results did not reveal smoking (p = 0.24) and drug use (p = 0.41) as predictors of SCS revision. The discrepancy of results may be due to fewer smokers (nonsmokers, n = 108 vs smokers, n = 33) and drug users (nondrug users, n = 124 vs drug users, n = 17) in our cohort. However, our results revealed that patients of younger age and male sex had a higher rate of revision compared with patients who were older and female. This finding can be explained by the active lifestyle and increased outdoor activities of a young male population (i.e., greater movement leads to a higher rate of lead migration) However, as would be suspected, there was no significant difference in the revision rate between races (white vs African American). Obese patients required more revisions than lean patients, but there was no significant difference in revision rates between patients with or without DM. In addition, patients with either a preimplantation pain score ≥ 8 or neuromuscular pain had higher rates of revision. This can be explained by the severity of local pain or local pain associated with muscular pain, either of which might have contributed to the requirement for more revisions in these cases. In this series, the failure of SCS implantation in patients with intractable low-back pain with neuromuscular pain (fibromyalgia) was due to either malfunction or nonfunction of the SCS. However, psychological factors might have also contributed to the SCS failure in these patients. Similarly, we also determined the predictor of requirement for early revision of SCS and found that a preimplantation pain score ≥ 8 was a positive predictor of early revision. However, there was no significant difference in revision rates between patients with or without depression.
limitations of the study
The present study has several limitations due to its retrospective nature. The SCS implantations were performed by various surgeons with different levels of surgical expertise, although most of the surgeries were performed by the senior author (B.G.).
Conclusions
Implantation of paddle lead SCS is a relatively less invasive procedure (compared with traditional spinal surgery [e.g., laminectomy]) that is safe and effective for patients with intractable back pain. Revision of the procedure de- pends on several factors, including younger age, male sex, associated neuromuscular pain, and severity of the pain. Therefore, patients with these factors who undergo SCS implantation should be closely followed for the possible requirement for revision. However, a randomized controlled trial in a large number of patients with intractable pain should be pursued to improve overall management or decrease the requirement for revision, identify the predictors of revision, and improve the quality of life of patients.
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